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Abstract
Background: In Korea, approximately 70% of HIV-positive individuals are currently diagnosed in hospitals, while
most HIV-positive patients were diagnosed at public health centers in 1980 s and 1990 s. However, there are no
reporting systems to identify how many HIV tests are performed in the Korean hospitals different from public
health centers and Blood centers. We estimated how many HIV tests were performed in hospitals and analyzed the
nationwide hospital-based HIV seroprevalence in the present study.
Methods: Between 2002 and 2008, data included HIV tests on insurance claims in hospitals and the proportion of
computerized insurance claims from the Health Insurance Review and Assessment Services. The number of HIV
tests from the survey in the External Quality Assurance Scheme for hospital laboratories was collected to calculate
the insurance claim proportion. HIV seroprevalence was estimated using data of tested individuals, including
infected individuals. Statistical analysis was confirmed with the 95% confidence interval. Statistical significance was
defined at p-values < 0.05.
Results: The number of HIV tests in hospitals increased from 2.7 million in 2002 to 5.0 million in 2008. The trend of
HIV seroprevalence was decrease (1.5-1.3 per 10,000 individuals, P < 0.0028), except in 2002. The number of
women tested was greater than men, and the proportion increased in older individuals and in small towns. Men
had a higher annual HIV seroprevalence than women (P < 0.0001). The annual seroprevalence decreased in men
(P = 0.0037), but was stable in women. The seroprevalence in the 30-39 year age group demonstrated higher than
other age groups except 2008.
Conclusions: The nationwide hospital-based number of HIV tests and seroprevalence were estimated using a new
method and seroprevalence trends were identified. This information will facilitate improvement in national HIV
prevention strategies.
Background
UNAIDS has provided basic information about the HIV/
AIDS epidemic by predicting the number of HIV-
infected individuals in each country, in addition to the
worldwide data [1,2]. The AIDS Epidemic software
(EPIMODEL) was developed by the WHO in the late
1980 s to estimate the past and current HIV prevalence,
and to make short-term projections of AIDS cases and
deaths in areas where AIDS case reporting was largely
incomplete and unreliable [3,4]. UNAIDS reported that
there are 33.4 million people living with HIV/AIDS
(PLWHA) worldwide, and 4.7 million HIV-positive indi-
viduals were alive in Asia in 2008 [5]. There is an enor-
mous difference in the national HIV prevalence among
Asian countries [6]. Specifically, south and southeast
Asia have a high prevalence, while Korea and Japan
have a low prevalence [7].
A total of 6888 cumulative HIV infections were identi-
fied in Korea as of 2009; 82% (5671) of these individuals
had been previously living with HIV/AIDS. The number
of newly diagnosed individuals is increasing annually [8].
It is unclear whether the increase is secondary to
increased transmission rates or to increased testing and
identification. We hoped to estimate the annual number
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HIV prevalence. However, the nationwide seroprevalence
and total number of HIV tests has not been estimated
because the number of HIV tests in the hospitals was
lacking.
The number of HIV tests in public health centers
(PHCs) decreased due to changes in strategies for HIV
testing from 1998 in Korea [9]. In contrast, the number
of HIV tests in hospitals has increased since 2000 due to
increased medical examinations, including regular health
check-ups, tests for pregnant women, and pre-surgical
testing. The current proportion of new HIV diagnoses in
h o s p i t a l si s7 0 %[ 1 0 ] .P H C sa n db l o o dc e n t e r sm a n a g e
data of HIV testing through a computerized system and
regularly report the number of HIV tests to the Korea
Centers for Disease Control and Prevention (KCDC)
[11-13]. However, there are no similar reporting systems
to identify how many HIV tests are performed in the
greater than 5000 Korean hospitals [14]. Hospital-derived
testing data is very important in the estimation of nation-
wide HIV seroprevalence, and prevalence models or esti-
mation methods are required to estimate the number of
HIV tests performed in the hospital.
The nationwide HIV seroprevalence is important for
AIDS prevention and evaluation of HIV testing strategies.
We therefore estimated the number of HIV tests and
HIV seroprevalence in hospitals. We developed a method
to estimate the number of HIV tests performed in hospi-
tals, calculated HIV seroprevalence in the hospital set-
ting, and analyzed the trends in HIV seroprevalence.
Methods
Data collection
Health insurance claims for HIV testing
National medical insurance is required for every citizen
of Korea. Hospitals claim medical costs to the Health
Insurance Review and Assessment Services (HIRA). Med-
ical costs are usually subsidized by the government when
HIV tests are performed for specific indications (sum-
marized in Figure 1 revised on 26 December 2008) [15],
and insurance claim data for HIV tests are collected from
HIRA to estimate the number of HIV tests performed in
hospitals. Claims for medical costs to HIRA are pro-
cessed on-line, or via compact disks (CDs) or documents.
Among the data, claims processed via documents are not
computerized. Computerized proportions by year and
hospital type are collected to adjust non-computerized
claims (Table 1). The number of yearly HIV tests and the
number of individuals who claimed insurance for HIV
tests are collected by gender, age, region, and hospital
type during 2002-2008. Regions are classified as metro-
politan or small town [11]. Hospitals are classified into
four hospital types, as follows: university medical center,
general hospital, clinic center, and private clinic.
The number of HIV tests by hospitals
For evaluation of proficiency in HIV tests, the External
Quality Assurance Scheme (EQAS) has been performed
for HIV testing laboratories every 6 months by the Divi-
sion of AIDS, with KCDC as the HIV national reference
laboratory. The number of HIV tests in hospital labora-
tories was surveyed through EQAS in 2005, 2006, and
2008 [16,17]. Therefore, we collected the number of
yearly HIV tests in each hospital in 2005, 2006, and
2008 from HIRA to estimate the insurance claim pro-
portions. Also, the number of HIV tests in private
clinics was collected from 24 main commercial clinical
laboratories because private clinics usually referred HIV
testing to the commercial clinical laboratories.
HIV-infected individuals
HIV-reactive cases from hospital as screening sites were
referred to the Division of AIDS at KCDC or 17 local sites
for the Institute of Health and Environment for confirma-
tion of HIV infection. Cases confirmed as positive were
reported to the Division of HIV and TB control at KCDC,
which manages the HIV Database. Hospital laboratories
usually use antigen/antibody Enzyme Linked Immunosor-
bent Assay (ELISA) test, Particle Agglutination Test (PA),
or Rapid test for HIV screening. Confirmation institutes
use antigen ELISA, antibody ELISA, PA, and Western Blot
for confirmation of HIV infection [18]. We collected HIV
cases data from the Division of HIV and TB control dur-
ing 2002-2008 for the estimation of HIV seroprevalence in
the present study.
Statistical methods
Assumptions for estimation of HIV seroprevalence
HIV seroprevalence was defined as the number of HIV-
infected individuals divided by the total number of HIV-
tested individuals in a single year during the study period.
HIV seroprevalence was estimated under several assump-
tions. First, the insurance claim proportions for HIV test-
ing by hospital type are similarly distribute in replying
and non-replying hospitals. Second, the insurance claim
proportions for HIV testing in the years without a survey
(2002-2004, and 2007) are similar to the nearest year
with a survey (2005, 2006, and 2008). Third, as the pro-
portion between the number of cases claimed for HIV
testing and the number of individuals claiming insurance,
the repeated value for an individual with an insurance
claim is similar to the repeated value for individuals with-
out an insurance claim.
Insurance claim proportion
In the years with a survey (2005, 2006, and 2008), only
hospitals with both the number of insurance claims for
HIV tests from HIRA and the number of HIV tests by the
HIV EQAS survey were classified by hospital type. Insur-
ance claim proportions for HIV testing were calculated as
the number of insurance claims divided by the number of
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Page 2 of 8Figure 1 Flowchart of insurance claim for HIV testing in hospitals.
Table 1 Computerization of insurance claim for HIV testing and the number of HIV tests per individual by year and
hospital type (2002-2008)
Hospital type Item 2002 2003 2004 2005 2006 2007 2008 P-value*
University medical center Computerization (%)
1) 89.6% 96.5% 99.1% 100% 100% 100% 100%
Repeated value
2) 1.046 1.048 1.048 1.045 1.055 1.059 1.069 0.0120
General hospital Computerization (%) 53.4% 73.4% 84.2% 94.8% 98.4% 97.7% 98.1%
Repeated value 1.028 1.030 1.032 1.029 1.037 1.057 1.050 0.0173
Clinic center Computerization (%) 25.9% 52.7% 71.5% 91.3% 96.7% 96.2% 98.4%
Repeated value 1.021 1.024 1.030 1.030 1.041 1.044 1.042 0.0008
Private clinic Computerization (%) 87.9% 90.7% 92.7% 94.8% 95.2% 95.3% 95.4%
Repeated value 1.091 1.103 1.112 1.104 1.101 1.102 1.077 0.4077
1)Data from Health Insurance Review and Assessment Services.
2)The number of HIV tests per individual for a year.
University medical center: Hospital with greater than 100 beds that provide more than 8 services of medical examination of patients with an associated medical
school.
General hospital: Hospital with greater than 100 beds that provide more than 8 services of medical examination of patients without an associated medical
school.
Clinic center: Hospital with 30-100 beds.
Private clinic: Private clinic with less than 30 beds that provide medical examination primarily on an outpatient basis.
*P-value for trend test of repeated value.
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years without a survey (2002-2004, and 2007) were esti-
mated. The insurance claim proportions for HIV testing
during 2002-2004 were estimated from 2005. The propor-
tion in 2007 was estimated as the mean of 2006 and 2008.
The number of HIV tests and the number of HIV-tested
individuals
The number of HIV tests was estimated as the number
of insurance claims with division by insurance claim
proportion and division by the computerized proportion
of insurance claims for HIV tests. The number of HIV-
tested individuals was calculated as the number of HIV
tests divided by the repeated value which was calculated
in each year by using the number of HIV tests divided
by the number of HIV-tested individuals from HIRA.
Estimation of HIV seroprevalence
Finally, HIV seroprevalence was represented as the
number of HIV-infected individuals per 10,000 HIV-
tested individuals in 1 year. The estimation of seropre-
valence by gender, age, and region was also performed.
Statistical analysis
The mean of repeated values by hospital types was com-
pared using ANOVA. The linearity of the repeated value
and the number of insurance claims by year in hospital
types was analyzed by trend tests. SAS 9.1 software was
used for the entire evaluation procedure. Statistical analy-
sis was confirmed with the 95% confidence interval (CI).
Statistical significance was defined at p-values < 0.05.
Results
The proportion of computerized insurance claims was
currently more than 95% (Table 1). General hospital
and clinic centers have increased for computerization of
insurance claims from 53.4% and 25.9% in 2002 to
98.1% and 98.4% in 2008, respectively. The repeated
values were the highest in private clinics (P < 0.0001);
however, the annual repeated value of private clinics
was not increasing (P = 0.4077).
The estimated number of HIV tests and insurance
claim proportions in hospitals are summarized, as
shown in Table 2. The total number of HIV tests in
hospitals increased from 2.8 million in 2002 to 5.0 mil-
lion in 2008, and also the number of insurance claims
for HIV tests increased annually in all hospital types
(P < 0.0001). The highest insurance claim proportion for
HIV tests was from university medical centers, followed
by general hospital and clinic centers.
Table 3 shows the estimated number of HIV-tested
individuals and HIV seroprevalence in hospitals. A total
of 2,662,715 individuals had HIV testing in hospitals in
2002. The estimated number increased to 4,774,625
individuals tested after ongoing annual increases.
Women were tested more frequently (53%) than men
(47%), and the aged 20-29 groups were higher in 2002
(21%) than in 2008 (16%, P = 0.0024), and the ≥60-year
age group was elevated (P < 0.0001). Small towns
showed an increasing proportion of tested individuals,
as follows: 26% in 2002; 35% in 2005; and 39% in 2008
(P < 0.0001).
The annual HIV seroprevalence was between 1.5 and
1.3 per 10,000 individuals between 2003 and 2008; how-
ever, HIV seroprevalence was lower in 2002 than other
years. Men had a higher seroprevalence than women
and decreased from 3.0 per 10,000 individuals to 2.5 per
10,000 individuals (P = 0.0037); however, the seropreva-
lence in women (around 0.2 per 10,000 individuals) was
stable between 2002 and 2008. The 30-39-year age
group had the highest annual HIV seroprevalence,
except in 2008, while the seroprevalence in the ≥60-year
age group was increased, but there was no statistically
significant difference (P = 0.0948). The annual HIV ser-
oprevalence was higher in metropolitan areas than small
towns, except in 2005.
Discussion
The nationwide hospital HIV seroprevalence was calcu-
lated using a new estimation method in the present
study. In 2008, the estimated number of HIV tests and
tested individuals in hospitals increased and reached 5.0
million and 4.8 million cases, respectively. The annual
HIV seroprevalence in hospitals was between 1.5 and
1.3 per 10,000 individuals during the study period,
except 2002. The annual number of HIV-tested indivi-
duals in PHCs was approximately 0.3 million and the
number in blood centers was approximately 1.6 million
in 2008 [12]. These data led to an estimated 6.6 million
as the total number of HIV-tested individuals, including
the test-takers at hospitals in the same year. Thus, it is
estimated that 13% of the Korean population (49 mil-
lion) are tested annually [19]. Of HIV infections, 70%
were diagnosed in hospitals, which performed 73% of
HIV tests in Korea in 2008. The seroprevalence of HIV
in hospitals was higher than the seroprevalence of HIV
in blood centers and lower than PHCs when compared
with previous results [13]. Most HIV infections diag-
nosed in hospitals were tested due to AIDS-related
symptoms, pre-surgical evaluations and regular health
check-ups [10]. The number of HIV-tested individuals
increased from 0.35 million in 2002 to 1.5 million in
2008; the increased number was supported by annual
data of tested individuals who sent insurance claims for
HIV tests to HIRA. This result confirmed the increase
in number of tested individuals per hospital and institu-
tion performing the tests. The main reason for increas-
ing HIV-tested individuals may be the effect of
advertisements for AIDS prevention through the mass
media (initiated in 2004) and the official announcement
of December as AIDS Test Days [20].
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in university medical centers is caused by the number of
cases including operation, transplantation and severe
diseases care which requires HIV test with insurance
(Figure 1).
T h es e r o p r e v a l e n c ei nw o m e nw a sl o w e rt h a nm e n ,
while more women were tested than men. Women
between 25 and 34 years of age were tested more fre-
quently than any other age group. This was likely due to
required HIV tests during pregnancy. Additionally, the
proportion of women ≥ 60 years of age is higher than
men, likely due to prolonged life spans in women [21].
We attempted to use statistical methods that would
reduce errors since a perfect estimation without errors
was not likely [4,22-24]. WHO/UNAIDS differentially
applied the results from serologic surveys of specific
groups, back-calculation methods, ratio methods, and
multiplication of estimated annual AIDS cases by
Table 2 Estimation of insurance claim proportion for HIV testing and the number of HIV test based on hospital type
in Korea (2002-2008)
Hospital type Item 2002 2003 2004 2005 2006 2007 2008
University medical center No. of institutes
† 42 42 43 42 43 43 43
No. of institutes participating
in survey (%
‡)*
- - - 38 (90.5%) 40 (93.0%) - 41 (95.3%)
Insurance claim proportion
for HIV test
§
33.9% 33.9% 33.9% 33.9% 39.7% 43.1% 46.5%
No. of insurance claims 188 006 232 114 268 914 311 852 408 904 480 238 560 928
Estimated number of HIV
tests
618 962 709 536 800 461 919 917 1 029 985 1 114 241 1 206 297
General hospital No. of institutes 241 241 163 215 242 249 268
No. of institutes participating
in survey (%
‡)
- - - 143 (66.5%) 164 (67.8%) - 141 (52.6%)
Insurance claim proportion
for HIV test
21.1% 21.1% 21.1% 21.1% 24.9% 31.7% 38.5%
No. of insurance claims 96 636 154 322 202 994 292 957 380 878 492 621 572 374
Estimated number of HIV
tests
857 660 996 436 1 142 585 1 465 580 1 554 503 1 590 593 1 515 480
Clinic center No. of institutes 783 871 314 470 573 759 888
No. of institutes participating
in survey (%
‡)
- - - 63 (13.4%) 77 (13.4%) - 78 (8.9%)
Insurance claim proportion
for HIV test
16.8% 16.8% 16.8% 16.8% 15.9% 19.2% 22.4%
No. of insurance claims 40 261 80 111 107848 134 546 189 783 250 976 330 385
Estimated number of HIV
tests
925 285 904 841 897 835 877 184 1 234 337 1 358 801 1 498 916
Private clinic No. of institutes 22 760 23 559 1913 2028 2267 2396 2448
No. of institutes participating
in survey (%)**
- - - 22 (1.1%) 24 (1.1%) - 23 (0.9%)
Insurance claim proportion
for HIV test
11.0% 11.0% 11.0% 11.0% 11.4% 12.4% 13.3%
No. of insurance claims 34 862 45 544 46 475 57 637 74 952 91 242 104 338
Estimated number of HIV
tests
360 555 456 490 455 771 552 714 690 624 772 112 822 323
Total No. of insurance claims 359 765 512 098 626 231 796 794 1 054 517 1 315 077 1 568 025
Estimated number of HIV test 2 762 462 3 067 303 3 296 653 3 814 395 4 509 448 4 835 747 5 043 015
†No. of institutes: Number of institutes claiming medical care fee for HIV testing to Health Insurance Review and Assessment Services (HIRA).
§Insurance claim proportion for HIV tests in years with survey (2005-2006, 2008). Without survey, insurance claim proportions for HIV tests during 2002-2004 were
estimated by that of 2005 and the proportion in 2007 was estimated as the mean of 2006 and 2008.
‡%: Proportion of institutes that participated in survey of EQAS among institutes claiming medical care fee for HIV testing to HIRA.
* Number of institutes participating in the survey of External Quality Assurance Scheme (EQAS) for HIV testing.
University medical center: Hospital with greater than 100 beds that provide more than 8 services of medical examination of patients with an associated medical school.
General hospital: Hospital with greater than 100 beds that provide more than 6 services of medical examination of patients without an associated medical school.
Clinic center: Hospital with 30-100 beds.
Private clinic: Private clinic with less than 30 beds that provide medical examination primarily on an outpatient basis.
**Data from private clinical laboratory because HIV tests in private clinics were usually sent to private clinical laboratories.
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Page 5 of 8Table 3 Estimation of the number of HIV- tested individuals and HIV seroprevalence in hospital in Korea (2002-2008)
2002 2003 2004 2005 2006 2007 2008
Category No. of
individuals
(%)
SP
(95%
CI)
No. of
individuals
(%)
SP
(95%
CI)
No. of
individuals
(%)
SP
(95%
CI)
No. of
individuals
(%)
SP
(95%
CI)
No. of
individuals
(%)
SP
(95%
CI)
No. of
individuals
(%)
SP
(95%
CI)
No. of
individuals
(%)
SP
(95%
CI)
Total 2662715 1.1
(1.0,1.3)
2942022 1.5
(1.3,1.6)
3152536 1.5
(1.3,1.6)
3655715 1.4
(1.3,1.6)
4288267 1.4
(1.2,1.5)
4559827 1.3
(1.2,1.4)
4774625 1.3
(1.2,1.4)
Gender
Men 1241385(47) 2.2
(1.9,2.5)
1366003 (46) 3.0
(2.7,3.3)
1475469(47) 2.9
(2.6,3.1)
1725043(47) 2.9
(2.6,3.1)
2029604(47) 2.6
(2.4,2.8)
2157016(47) 2.5
(2.3,2.7)
2283012(48) 2.5
(2.3,2.7)
Women 1421330(53) 0.2
(0.1,0.3)
1576019(54) 0.2
(0.1,0.3)
1677067(53) 0.2
(0.2,0.3)
1930672(53) 0.1
(0.1,0.2)
2258663(53) 0.2
(0.2,0.3)
2402811(53) 0.2
(0.1,0.2)
2491613(52) 0.2
(0.1,0.2)
Age(years)
<20 230182(14) 0.2
(0.0,0.3)
265790(14) 0.2
(0.0,0.4)
286719(14) 0.2
(0.0,0.3)
327129(14) 0.2
(0.1,0.4)
368356(14) 0.2
(0.1,0.4)
575860(13) 0.2
(0.1,0.3)
391628(13) 0.3
(0.1,0.4)
20-29 415085(21) 1.4
(1.0,1.7)
427927(20) 1.8
(1.4,2.2)
428347(18) 2.1
(1.7,2.6)
483521(17) 1.6
(1.2,2.0)
564369(17) 1.6
(1.3,2.0)
359699(17) 2.1
(1.7,2.6)
583999(16) 1.5
(1.2,1.8)
30-39 551075(20) 1.7
(1.3,2.0)
579531(19) 2.7
(2.3,3.1)
594234(18) 2.8
(2.4,3.2)
656387(18) 2.8
(2.4,3.2)
753751(17) 2.3
(2.0,2.7)
770464(17) 2.1
(1.8,2.5)
795353(16) 2.0
(1.7.,2.3)
40-49 527384(17) 1.6
(1.3,1.9)
579015(17) 2.0
(1.6,2.4)
609748(17) 1.9
(1.5,2.2)
698571(18) 1.8
(1.5,2.2)
816613(19) 1.8
(1.5,2.0)
754847(19) 2.0
(1.7,2.4)
867318(19) 2.2
(1.9,2.5)
50-59 379374(14) 1.2
(0.8,1.5)
429129(15) 1.3
(1.0,1.7)
465895(15) 1.2
(0.9,1.5)
560005(15) 1.6
(1.3,1.9)
682309(15) 1.4
(1.1,1.7)
855980(15) 1.1
(0.9,1.3)
802645(15) 1.5
(1.3,1.8)
60≤ 559617(14) 0.3
(0.,0.5)
660629(15) 0.3
(0.2,0.5)
767593(17) 0.4
(0.3,0.5)
930102(18) 0.4
(0.3,0.5)
1102869(18) 0.6
(0.5,0.7)
1242976(20) 0.6
(0.5,0.7)
1333682(21) 0.4
(0.3,0.5)
Region
Metropolitan 1 961671(74) 1.2
(1.0,1.3)
2 114283(72) 1.5
(1.3,1.6)
2155559(68) 1.6
(1.4,1.8)
2 368915(65) 1.4
(1.2,1.5)
2674029(62) 1.6
(1.4,1.7)
2799223(61) 1.6
(1.4,1.7)
2 917391(61) 1.6
(1.4,1.7)
Small town 701044(26) 1.0
(0.8,1.3)
827739(28) 1.4
(1.2,1.7)
996977(32) 1.2
(1.0,1.4)
1286800(35) 1.5
(1.3,1.7)
1614238(38) 1.0
(0.8,1.1)
1760604(39) 0.7
(0.6,0.8)
1 857234(39) 0.9
(0.8,1.1)
No. of individuals: Number of HIV-tested individuals, SP: HIV Seroprevalence per 10000 individuals, CI: Confidence Interval.
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820 according to factors, including year and population
characteristics [4]. These estimation methods might be
affected by data quality, representation rate, and model-
ing assumptions to result in errors. Therefore, estima-
tion methods were improved by development of new
methods (workbook method and special computer
method) and tool standards to achieve superior estima-
tions [22-24].
UNAIDS currently estimates the HIV prevalence of
each country by reflecting population and characteristics
through national surveillance and specific surveillance in
high-risk groups [1,25,26]. This estimated that 13,000
HIV-infected individuals (95% CI, 7,500-42,000) have
survived, and HIV prevalence in individuals 15-49 years
of age was estimated at 0.040% (95% CI, 0.00-0.100) in
Korea in 2007 [27]. However, we estimated that the
nationwide HIV seroprevalence was 0.014% (95% CI,
0.011-0.016) after adjustment for age and gender in the
same year. This seroprevalence was estimated for HIV
seroprevalence of PHC visitors (0.043%; 95% CI, 0.027-
0.060), blood donors (0.003%; 95% CI, 0.001-0.005) [13],
and hospital visitors (0.015%; 95% CI, 0.012-0.018). The
estimated HIV seroprevalence in this study was lower
than UNAIDS estimation.
WHO/UNAIDS estimated current Korean HIV/AIDS
data based on KCDC reports. This reflected some basic
factors, including population, birth rate, death rate, and
the number of HIV-infected individuals. However, it did
not include advanced factors, such as current prevalence
by institutional types or risk groups. The estimated
value by the AIDS prediction model (EPP) will be most
similar to the true value when it includes as many fac-
tors related to HIV prevalence as possible. Therefore, a
survey by KCDC should be expanded to more factors
affecting WHO/UNAIDS evaluation. UNAIDS estima-
tion used only basic factors, while HIV seroprevalence
in this study was estimated using information, such as
data from EQAS survey, insurance claim data, and data
for HIV tests in blood centers and PHCs. Because of
this difference, we think that our results may be closer
to the true value than UNAIDS estimation.
In our study, estimation of HIV-tested individuals
using insurance data and hospital surveys can include
several limitations. First, the number of surveys for
clinic centers and private clinics are not as large as
other hospital types. However, 12% of clinic centers are
not too low by sampling methods for estimation [28].
Also, the number of tests in private clinics substituted
from commercial clinical laboratories was likely accurate
because most of the commercial clinical laboratories
participated in the survey. Our results can include bias
in insurance claim proportions for HIV tests by sur-
veyed hospitals per year [29]. Second, there are some
years in which surveys are missing. Without surveys,
insurance claim proportions for HIV tests during
2002-2004 were estimated by that of 2005. Estimation of
2007 was reasonable because it was estimated as the
mean of 2006 and 2008, but estimations for 2002
through 2004 appear to be biased and the value near
year 2002 has more bias than the true value. There is a
need to survey the number of HIV tests in hospitals per
year to precisely estimate the insurance claim propor-
tion for HIV tests. Finally, repeated values may be differ-
ent between individuals with and without insurance
claims. We are aware that there could be some bias in
the prevalence estimated in the present study. Indeed,
previous studies have identified potential biases in asses-
sing the general population HIV prevalence from sam-
ples of selected groups such as prenatal clinic users,
blood donors and hospital-based studies [30,31]. How-
ever, the repeated value for individuals with insurance
claims was similar to the value of HIV-tested individuals
during health check-ups in PHCs [11]. This report could
enforce our assumption for the estimation method.
Conclusions
The analytical adjustment using the estimation of insur-
ance claim proportion and proportion of computerized
insurance claims was applied to reduce errors in this
study. The nationwide HIV seroprevalence and total
number of HIV tests based in hospitals were also esti-
mated using new methods developed and the seropreva-
lence trend was identified. This estimation may supply
important basic data to revise AIDS strategies for better
control.
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